NCT05178043View on ClinicalTrials.gov

GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

August 1, 2021

Primary Completion Date

April 1, 2025

Study Completion Date

December 1, 2025

Conditions
Hepatocellular CarcinomaHCC
Interventions
DRUG

Nivolumab

Nivolumab 240mg to be administered as an intravenous (IV) infusion every 2 weeks (Q2W).

DRUG

GT90001

GT90001 7mg/kg to be administered as an intravenous infusion every 2 weeks (Q2W) after Nivolumab infusion.

Trial Locations (5)

10016

NYU Langone Health, New York

77056

Renovatio Clinical, Houston

90017

Los Angeles Hematology Oncology Medical Group, Los Angeles

91010

City of Hope National Medical Center, Duarte

99208

Medical Oncology Associates, Spokane

All Listed Sponsors
lead

Suzhou Kintor Pharmaceutical Inc,

INDUSTRY

NCT05178043 - GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter